Indication
Homozygous familial hypercholesterolemia
Homozygous familial hypercholesterolemia is a rare, life-threatening genetic metabolic disorder affecting the cardiovascular system, caused by biallelic pathogenic mutations in genes critical to low-density lipoprotein clearance, most commonly the low-density lipoprotein receptor gene. Read more about Homozygous familial hypercholesterolemia
189 drugs 97 manufacturers
Drugs that treat it
Common Homozygous familial hypercholesterolemia therapies.
ATORVASTATIN CALCIUM
ATORVASTATIN CALCIUM
ATORVASTATIN CALCIUM
ROSUVASTATIN CALCIUM
ROSUVASTATIN CALCIUM
ATORVASTATIN CALCIUM
EZETIMIBE
ROSUVASTATIN CALCIUM
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonHomozygous familial hypercholesterolemia is a rare, life-threatening genetic metabolic disorder affecting the cardiovascular system, caused by biallelic pathogenic mutations in genes critical to low-density lipoprotein clearance, most commonly the low-density lipoprotein receptor gene.
This condition primarily manifests in children and young adults and is pathophysiologically defined by absent or severely blunted low-density lipoprotein receptor function, resulting in profound elevations of circulating low-density lipoprotein cholesterol typically exceeding 400 to 500 mg/dL.
Clinically, affected individuals develop physical signs of lipid deposition—such as cutaneous planar, tendon, or tuberous xanthomas and corneal arcus—alongside accelerated, premature atherosclerotic cardiovascular disease, aortic stenosis, and ischemic cardiac events often presenting before the second or third decade of life.
- nih.gov
Homozygous familial hypercholesterolemia is a rare, life-threatening genetic metabolic disorder affecting the cardiovascular system, caused by biallelic pathogenic mutations in genes critical to low-density lipoprotein clearance, most commonly the low-density lipoprotein receptor gene
- nih.gov
Homozygous familial hypercholesterolemia is a rare, life-threatening genetic metabolic disorder affecting the cardiovascular system, caused by biallelic pathogenic mutations in genes critical to low-density lipoprotein clearance, most commonly the low-density lipoprotein receptor gene This condition primarily manifests in children and young adults and is pathophysiologically defined by absent or severely blunted low-density lipoprotein receptor function, resulting in profound elevations of circu...
- heart.org
This condition primarily manifests in children and young adults and is pathophysiologically defined by absent or severely blunted low-density lipoprotein receptor function, resulting in profound elevations of circulating low-density lipoprotein cholesterol typically exceeding 400 to 500 mg/dL
- rarediseases.org
Clinically, affected individuals develop physical signs of lipid deposition—such as cutaneous planar, tendon, or tuberous xanthomas and corneal arcus—alongside accelerated, premature atherosclerotic cardiovascular disease, aortic stenosis, and ischemic cardiac events often presenting before the second or third decade of life
- optum.com
Clinically, affected individuals develop physical signs of lipid deposition—such as cutaneous planar, tendon, or tuberous xanthomas and corneal arcus—alongside accelerated, premature atherosclerotic cardiovascular disease, aortic stenosis, and ischemic cardiac events often presenting before the second or third decade of life
Personalize your experience
Follow Homozygous familial hypercholesterolemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.